share_log

Transcode Therapeutics | 8-K: Current report

SEC announcement ·  Jan 31 16:39
Summary by Moomoo AI
TransCode Therapeutics, Inc., an RNA oncology company, has regained compliance with the Nasdaq's stockholders' equity requirement for continued listing on the Nasdaq Capital Market, as notified by the Nasdaq Office of General Counsel on January 26, 2024. The company, which is listed under the trading symbol RNAZ, had previously been out of compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000. Following the compliance, TransCode will be monitored by a mandatory panel through January 26, 2025. Additionally, TransCode received a separate notification from Nasdaq on November 7, 2023, regarding non-compliance with the minimum bid price rule. The company must maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days before May 6, 2024, to regain compliance. TransCode is a clinical-stage company focused on developing RNA therapeutics for treating metastatic cancer, with its lead candidate, TTX-MC138, targeting metastatic tumors.
TransCode Therapeutics, Inc., an RNA oncology company, has regained compliance with the Nasdaq's stockholders' equity requirement for continued listing on the Nasdaq Capital Market, as notified by the Nasdaq Office of General Counsel on January 26, 2024. The company, which is listed under the trading symbol RNAZ, had previously been out of compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000. Following the compliance, TransCode will be monitored by a mandatory panel through January 26, 2025. Additionally, TransCode received a separate notification from Nasdaq on November 7, 2023, regarding non-compliance with the minimum bid price rule. The company must maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days before May 6, 2024, to regain compliance. TransCode is a clinical-stage company focused on developing RNA therapeutics for treating metastatic cancer, with its lead candidate, TTX-MC138, targeting metastatic tumors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more